Characterization of sleep-disordered breathing in children with Duchenne muscular dystrophy by the American Academy of Sleep Medicine criteria vs disease-specific criteria: what are the differences?

Non‐invasive ventilation usage and adherence in children and adults with Duchenne muscular dystrophy: A multicenter analysis

“…Certain centers may initiate NIV sooner when the perceived benefit of NIV in DMD patients is not as apparent. Further, recent guidelines 3 for DMD patients will identify SDB, particularly NH, far earlier in children 8 . Earlier diagnosis of SDB will likely yield more prescriptions of NIV in younger patients with DMD.…”

“…Given the progressive loss of muscle strength, respiratory disease is a major cause of morbidity and mortality 2–4 . Affected individuals often first develop sleep‐disordered breathing (SDB) including obstructive sleep apnea (OSA), which is most common, central sleep apnea and/or nocturnal hypoventilation (NH) 1–8 . The severity of OSA is linearly related to high body mass index (BMI) secondary to a loss of ambulation as well as glucocorticoid therapy 7 .…”

“…Non‐invasive ventilation (NIV) is often prescribed for the management of SDB and chronic respiratory insufficiency in individuals with DMD 1–3 . There remain variations in clinical practice regarding NIV prescription, including evolving guidelines for recognition of indications for NIV 8 . In this context, studies evaluating NIV in patient populations have greater validity if they incorporate a multi‐center approach to integrate a wide array of opinions.…”

“…[2][3][4] Affected individuals often first develop sleep-disordered breathing (SDB) including obstructive sleep apnea (OSA), which is most common, central sleep apnea and/or nocturnal hypoventilation (NH). [1][2][3][4][5][6][7][8] The severity of OSA is linearly related to high body mass index (BMI) secondary to a loss of ambulation as well as glucocorticoid therapy. 7 NH has been reported in older subjects with DMD with advanced muscular weakness likely signifying progressive restrictive lung disease.…”

“…[1][2][3] There remain variations in clinical practice regarding NIV prescription, including evolving guidelines for recognition of indications for NIV. 8 In this context, studies evaluating NIV in patient populations have greater validity if they incorporate a multi-center approach to integrate a wide array of opinions. Nonetheless, NIV has been shown to prolong survival, optimize quality of life and well-being as well as reduce the progression of lung function decline.…”